by Reuters on (#6Y0VZ)
Anne Wojcicki made $305m bid for firm, which has lost customers since declaring bankruptcy, with backing of Fortune 500 company23andMe's former CEO is set to regain control of the genetic testing company after a $305m bid from a non-profit she controls topped a pharmaceutical company's offer for it in a bankruptcy auction.Last month, Regeneron Pharmaceuticals agreed to buy the firm for $256m, topping a $146m bid from Anne Wojcicki and the non-profit TTAM Research Institute. The larger offer prompted Wojcicki to raise her own with the backing of a Fortune 500 company, according to the former executive. The deal is expected to close in the coming weeks after a court hearing currently scheduled for 17 June, the company said on Friday. Continue reading...